Clinical Trial

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated September 2024 completion). Its status may not reflect the trial's current state.
Summary
This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-12-16; most recent amendment 2024-08-19.
Status change: Recruiting → Active, Not Recruiting 2024-08-19
Status change: Not Yet Recruiting → Recruiting 2023-02-21
Trial Details
NCT Number NCT05665751
Lead Sponsor OrsoBio, Inc
Conditions Insulin Resistance
Enrollment 76 participants
Start Date 2023-03-08
Primary Completion 2024-09 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-20